PRNewsWire
15 Jun 2026, 20:40 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Enliven Therapeutics closed an upsized public offering of common stock and pre-funded warrants, raising approximately $460.0 million in gross proceeds. — A massive cash infusion significantly extends the runway for a clinical-stage biotech company, reducing immediate bankruptcy risk and funding R&D.
+0.60The offering resulted in the issuance of over 10.5 million new shares and pre-funded warrants at a price of $37.50 per share. — The issuance of millions of new shares creates significant equity dilution for existing shareholders.
-0.40The offering included the full exercise of the underwriters' option to purchase an additional 1.6 million shares. — Full exercise of the over-allotment option indicates strong institutional demand for the company's equity.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully closed an upsized public offering, raising approximately $460 million in gross proceeds.
Acted as a joint book-running manager for a successful $460 million offering.
Acted as a joint book-running manager for a successful $460 million offering.
Acted as a joint book-running manager for a successful $460 million offering.
[a_to_b] Goldman Sachs acted as a joint book-running manager for Enliven Therapeutics' public offering.
[a_to_b] Morgan Stanley acted as a joint book-running manager for Enliven Therapeutics' public offering.
[a_to_b] Barclays acted as a joint book-running manager for Enliven Therapeutics' public offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
